Erlotinib
ATC Code
L01XE03
Erlotinib
Definition
A quinazoline derivative with antineoplastic properties. Competing with adenosine triphosphate, erlotinib reversibly binds to the intracellular catalytic domain of epidermal growth factor receptor (EGFR) tyrosine kinase, thereby reversibly inhibiting EGFR phosphorylation and blocking the signal transduction events and tumorigenic effects associated with EGFR activation.
Also known as ERLOTINIB — per NCIT
Also identified as
- ATC L01EB per NCIT
- NCIT NCIT:C65530 per NCIT
Indications
| Disease | Relation | Source |
|---|---|---|
| Non-small cell lung carcinoma | may treat | MEDRT · Public domain (U.S. Government work) |
Organ Effects
| Organ | Side effect / interaction | Source |
|---|---|---|
| Lungs | may treat a disease of this organ | DERIVED · CC BY 4.0 |
1 entry above is marked DERIVED: Atlas Médico inferred it by combining two sourced claims, and no source asserts this link directly. Treat it as a navigation aid, not as a clinical statement.